Friday, 29 March 2024


3SBio to join global ph III trial for Voclosporin

29 June 2012 | Regulatory | By BioSpectrum Bureau

3SBio to join global ph III trial for Voclosporin

This will be a phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients

This will be a phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients

Singapore: 3SBio, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, has received State Food and Drug Administration (SFDA) approval to conduct the China arm of the multi-center phase III trial of voclosporin, a new generation calcineurin inhibitor licensed from Japan's Isotechnika Pharma.

According to the approved protocol, this will be a phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients. Patient enrollment is expected to begin in the third quarter of 2012.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account